Additionally, future studies investigating how FXR modulates SOCS3 and consequently impacts STAT3 signaling in CSCs could facilitate the development of more effective treatments aimed at disrupting the CSCs, ultimately improving patient outcomes across various cancer types. The gene discussed is SOCS3; the disease is cancer.